On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.

On the news front, the company reported its fiscal fourth quarter and full-year financial results for the period ended March 31, alongside a comprehensive business progress update. Fiscal Q4 earnings per share from continuing operations came in at $0.28, while quarterly revenue of $2.52 million missed the consensus estimate of $3.82 million. Despite the revenue shortfall, the concurrent disclosure of business developments received a positive market response, driving the stock higher in pre-market trading.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. The company operates through its Vant model, building focused subsidiaries across biopharmaceutical businesses and health technology startups. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)